

# ORANDA THERAPEUTICS SECURES START-UP FUNDING AND FIRST MARKETING AUTHORISATION

*Investors back new Irish-headquartered company to support its mission, championing accessibility to rare disease medicines*

LONDON, UNITED KINGDOM, April 27, 2026 /EINPresswire.com/ -- Start-up biopharma company



We are a company founded on innovation, entrepreneurship and agility with a deliberate and purposeful approach to identifying opportunities to broaden access to new and existing rare disease medicines”

*Ahmed Al-Derzi*

[Oranda Therapeutics \(Oranda\) has concluded a start-up funding round](#), led by Business Venture Partners (BVP), an Irish based multi-asset investment platform. Additional funding has been secured from Integrated Finance Group (IFG) of the United States.

The funding will allow Oranda to pursue its mission of [supporting European patients in accessing rare disease medicines](#). Oranda Co-founder and CEO, Ahmed Al-Derzi, said: “We’re very excited to complete our initial funding round. Oranda is a company that aims to make a meaningful contribution to the lives of those living with rare disease and their families. We are a company founded

on innovation, entrepreneurship and agility with a deliberate and purposeful approach to identifying opportunities to broaden access to new and existing rare disease medicines in Europe.”

Elliott Griffin, Managing Director, BVP Investments, said: “With several significant orphan medicines for rare diseases due to lose market exclusivity from 2026 onwards, the opportunity to broaden patient access through more affordable alternatives is both commercially compelling and socially important. Today, fewer than half of approved orphan medicines are available to patients across Europe and that is a gap Oranda is uniquely positioned to address. The Oranda team bring decades of rare disease commercialisation experience, alongside a track record of building and scaling biopharma businesses to a clear, execution-ready plan. We are delighted to back them as they build a best-in-class European rare disease platform.”

Having been [granted its first marketing authorisation for nintendanib](#) for the treatment of adults

with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF) in Germany, the commercial build out of Oranda across Europe is underway. Uwe Mayer joins the Oranda team as General Manager, Germany. Uwe brings 20 years' leadership experience in rare diseases, commercial strategy and operational excellence. He joins having held senior commercial roles at Jazz Pharmaceuticals and Novartis Gene Therapies. Oranda also recently welcomed Dr Kieran Rooney, formerly of Amryt Pharma, to its board as Non-Executive Director.

John Irwin, Oranda's Co-founder and CCO, said: "We're delighted to welcome Uwe and Kieran to the Oranda team; individuals with exceptional track records in medicine commercialisation and biopharma business and corporate development respectively. They join us at a pivotal time as we gain our first marketing authorisation and prepare for our initial product launch in late 2026."

- Ends -

Notes to editors

Oranda Therapeutics is a rare disease company, focused on acquiring, co-developing and commercialising innovative treatments to help improve the lives of patients in areas of high unmet need. The company has a portfolio of late-stage rare disease assets with first European launch scheduled for late 2026.


The company is headquartered in Dublin, Ireland.

For more information on Oranda, please see [www.orandatherapeutics.com](http://www.orandatherapeutics.com).

BVP is an Irish, multi-asset investment platform that partners with companies that have the global ambition and the vision to make a positive impact on the world.

For more information on BVP, please see [www.bvp.ie](http://www.bvp.ie).

IFG is the capital partner of Actum Pharma, a US based strategy and operating business partner to global biopharma manufacturers focused on rare diseases, orphan drugs, and complex



**ORANDA**  
**THERAPEUTICS**

Start-up biopharma company Oranda Therapeutics

conditions.

For more information on Actum Pharma, please see [www.actumpharma.com](http://www.actumpharma.com).

For media enquiries, please contact Richard Oakley, Oxygen Health Communications, [richard@oxygenmediacomms.com](mailto:richard@oxygenmediacomms.com).

Mr Richard J Oakley  
Oxygen Health Communications Ltd  
[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/908414135>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.